<DOC>
	<DOCNO>NCT01185847</DOCNO>
	<brief_summary>This open label , 2-part study evaluate safety efficacy RO5083945 combination standard chemotherapy patient advanced recurrent non-small cell lung cancer receive prior chemotherapy . In Part 1 patient receive RO5083945 intravenously standard chemotherapy ( cisplatin plus either gemcitabine pemetrexed ) 6 cycle 3 week RO5083945 disease progression . In Part 2 patient randomize receive either RO5083945 combination standard chemotherapy chemotherapy alone 6 cycle . In absence disease progression , patient receive RO503945 continue treatment RO5083945 monotherapy .</brief_summary>
	<brief_title>A Study RO5083945 Combination With Chemotherapy Versus Chemotherapy Alone Patients With Advanced Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Advanced ( IIIb ) , metastatic ( IV ) recurrent nonsmall cell lung cancer At least 1 measurable disease lesion per RECIST criterion Confirmed presence EGFR tumor tissue ECOG performance status 01 Adequate hematological , renal liver function Prior chemotherapy treatment another systemic anticancer agent Radiotherapy within last 4 week , except limited field palliative radiotherapy bone pain relief Symptomatic active CNS metastasis Recent history poorly control hypertension ( systolic &gt; 180mmHg diastolic &gt; 100mmHg ) Requirement steroid &gt; 40 mg prednisolone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>